Display options
Cite
Thijs L, Staessen JA, Beleva S, et al. How well can blood pressure be controlled? Progress report on the Systolic Hypertension in Europe Follow-Up Study (Syst-Eur 2). Curr Control Trials Cardiovasc Med. 2001;2(6):298-306doi: 10.1186/cvm-2-6-298.
Thijs, L., Staessen, J. A., Beleva, S., Birkenhäger, W. H., Bulpitt, C. J., Celis, H., Fletcher, A. E., Kermova, R., Leonetti, G., Laks, T., Mantov, S., Nachev, C., Sarti, C., Tuomilehto, J., Fagard, R. H. (2001). How well can blood pressure be controlled? Progress report on the Systolic Hypertension in Europe Follow-Up Study (Syst-Eur 2). Current controlled trials in cardiovascular medicine, 2(6), 298-306. https://doi.org/10.1186/cvm-2-6-298
Thijs, Lutgarde, et al. "How well can blood pressure be controlled? Progress report on the Systolic Hypertension in Europe Follow-Up Study (Syst-Eur 2)." Current controlled trials in cardiovascular medicine vol. 2,6 (2001): 298-306. doi: https://doi.org/10.1186/cvm-2-6-298
Thijs L, Staessen JA, Beleva S, Birkenhäger WH, Bulpitt CJ, Celis H, Fletcher AE, Kermova R, Leonetti G, Laks T, Mantov S, Nachev C, Sarti C, Tuomilehto J, Fagard RH. How well can blood pressure be controlled? Progress report on the Systolic Hypertension in Europe Follow-Up Study (Syst-Eur 2). Curr Control Trials Cardiovasc Med. 2001 Oct 18;2(6):298-306. doi: 10.1186/cvm-2-6-298. PMID: 11806817; PMCID: PMC64833.
Copy Download .nbib Format: NLM
Share it on

Curr Control Trials Cardiovasc Med. 2001 Oct 18;2(6):298-306. doi: 10.1186/cvm-2-6-298.

How well can blood pressure be controlled? Progress report on the Systolic Hypertension in Europe Follow-Up Study (Syst-Eur 2).

Current controlled trials in cardiovascular medicine

Lutgarde Thijs, Jan A Staessen, Sonia Beleva, Willem H Birkenhäger, Christopher J Bulpitt, Hilde Celis, Astrid E Fletcher, Rumjana Kermova, Gastone Leonetti, Tovio Laks, Stefan Mantov, Choudomir Nachev, Cinzia Sarti, Jaakko Tuomilehto, Robert H Fagard,

Affiliations

  1. Hypertensie en Cardiovasculaire Revalidatie Eenheid, Katholieke Universiteit Leuven, Leuven, Belgium. [email protected]

PMID: 11806817 PMCID: PMC64833 DOI: 10.1186/cvm-2-6-298

Abstract

BACKGROUND: The randomised, double-blind, placebo-controlled Systolic Hypertension in Europe trial (Syst-Eur 1) proved that blood pressure (BP) lowering therapy starting with nitrendipine reduces the risk of cardiovascular complications in elderly patients with isolated systolic hypertension. In an attempt to confirm the safety of long-term antihypertensive therapy based on a dihydropyridine, the Syst-Eur patients remained in open follow-up after the end of Syst-Eur 1. This paper presents the second progress report of this follow-up study (Syst-Eur 2). It describes BP control and adherence to study medications. METHODS: After the end of Syst-Eur 1 all patients, treated either actively or with placebo, were invited either to continue or to start antihypertensive treatment with the same drugs as previously used in the active treatment arm. In order to reach the target BP (sitting SBP <150 mmHg), the first line agent, nitrendipine, could be associated with enalapril and/or hydrochlorothiazide. RESULTS: Of the 3787 eligible patients, 3516 (93%) entered Syst-Eur 2. At the last available visit, 72% of the patients were taking nitrendipine. SBP/DBP at entry in Syst-Eur 2 averaged 160/83 mmHg in the former placebo group and 151/80 mmHg in the former active-treatment group. At the last follow-up visit SBP/DBP in the patients previously randomised to placebo or active treatment had decreased by 16/5 mmHg and 7/5 mmHg, respectively. The target BP was reached by 74% of the patients. CONCLUSION: Substantial reductions in systolic BP may be achieved in older patients with isolated systolic hypertension with a treatment strategy starting with the dihydropyridine calcium-channel blocker, nitrendipine, with the possible addition of enalapril and/or hydrochlorothiazide.

References

  1. Lancet. 1997 Sep 13;350(9080):757-64 - PubMed
  2. Circulation. 2000 Sep 5;102(10):1079-81 - PubMed
  3. J Hypertens. 1998 Dec;16(12 Pt 1):1823-9 - PubMed
  4. J Hypertens. 1996 Oct;14(10):1237-45 - PubMed
  5. J Hypertens. 1999 Feb;17(2):151-83 - PubMed
  6. JAMA. 2000 Apr 19;283(15):1967-75 - PubMed
  7. Arch Intern Med. 1997 Nov 24;157(21):2413-46 - PubMed
  8. BMJ. 1999 Sep 4;319(7210):630-5 - PubMed
  9. Arch Intern Med. 1999 Sep 27;159(17):2004-9 - PubMed
  10. J Hum Hypertens. 1999 Feb;13(2):135-45 - PubMed
  11. Hypertension. 1999 Dec;34(6):1181-5 - PubMed
  12. Arch Intern Med. 1998 Aug 10-24;158(15):1681-91 - PubMed
  13. Lancet. 1998 Jun 13;351(9118):1755-62 - PubMed
  14. Lancet. 2000 Jul 29;356(9227):366-72 - PubMed
  15. Lancet. 2000 Jul 29;356(9227):359-65 - PubMed
  16. Hypertension. 1999 Jun;33(6):1476-7 - PubMed
  17. CMAJ. 1999;161 Suppl 12:S1-17 - PubMed
  18. Lancet. 1999 Nov 20;354(9192):1751-6 - PubMed

Publication Types